The term atypical hemolytic uremic syndrome has been in use since the mid-1970s. It was initially used to describe the familial or sporadic form of hemolytic uremic syndrome as opposed to the epidemic, typical form of the disease. Over time, the atypical hemolytic uremic syndrome term has evolved into being used to refer to anything that is not Shiga toxin-associated hemolytic uremic syndrome. The term describes a heterogeneous group of diseases of disparate causes, a circumstance that makes defining disease-specific natural history and/or targeted treatment approaches challenging. A working group of specialty-specific experts in the thrombotic microangiopathies was convened to review the validity of this broad term in an era of swiftly advancing science and targeted therapeutics. A Delphi approach was used to define and interrogate some of the key issues related to the atypical hemolytic uremic syndrome nomenclature.

中文翻译：

---

关于非典型溶血性尿毒症综合征命名的专家讨论——确定精确路线图：国家肾脏基金会工作组的报告。


非典型溶血性尿毒症综合征这一术语自 20 世纪 70 年代中期以来一直在使用。它最初用于描述家族性或散发性溶血性尿毒症综合征，而不是流行性的典型疾病形式。随着时间的推移，非典型溶血性尿毒症综合征一词已演变为用来指代除志贺毒素相关的溶血性尿毒症综合征之外的任何事物。该术语描述了一组具有不同原因的异质疾病，这种情况使得定义特定疾病的自然史和/或有针对性的治疗方法具有挑战性。血栓性微血管病领域的专业专家组成的工作组被召集起来，以审查这个广泛术语在科学和靶向治疗迅速发展的时代的有效性。使用德尔菲法来定义和询问与非典型溶血性尿毒症综合征命名相关的一些关键问题。